NYMC Faculty Publications
Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial
Journal Title
European Journal of Heart Failure
First Page
359
Last Page
369
Document Type
Article
Publication Date
2-1-2018
Department
Medicine
Abstract
AIMS: To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial. METHODS AND RESULTS: Two thousand five hundred and sixty-nine patients with HFrEF (ejection fraction
Recommended Citation
Lam, P. H., Fonarow, G., Butler, J., White, M., Aronow, W., Pitt, B., & Ahmed, A. (2018). Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial. European Journal of Heart Failure, 20 (2), 359-369. https://doi.org/10.1002/ejhf.937
